Japan, July 14 -- ADRENOMED AG has got intellectual property rights for 'ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTIBODY FRAGMENT OR ANTI-ADM NON-IG SCAFFOLD FOR USE IN INTERVENTION AND THERAPY OF CONGESTION IN PATIENT IN NEED THEREOF.' Other related details are as follows:
Application Number: JP,2023-009286
Category (FI): C12N15/13,C07K14/575,C12N15/16,C12P21/08,A61K39/395@D,A61K39/395@N,A61P1/16,A61P13/12,A61P43/00,111,A61P7/10,A61P9/12,A61P9/04,A61P9/00,C07K16/26
Stage: PROBLEM TO BE SOLVED: To provide an anti-Adrenomedullin (ADM) antibody or an anti-Adrenomedullin antibody fragment or an anti-ADM non-lg scaffold for use in intervention and therapy of congestion in a patient in need thereof.SOLUTION: Subject matter of the present invention is an anti-Adrenomedullin (ADM) antibody or an anti-Adrenomedullin antibody fragment or an anti-ADM non-lg scaffold for use in intervention and therapy of congestion in a patient in need thereof.SELECTED DRAWING: None (Grant)
Filing Date: Jan. 25, 2023
Publication Date: April 11, 2023
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
